MC
XENT

Moors & Cabot’s Intersect ENT, Inc XENT Stock Holding History

Moors & Cabot’s Portfolio XENT Stock Details XENT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-6,600
Closed -$211K – 613
2017
Q4 		$211K Sell
6,600
-250
-4% -$7.5K 0.03% 507
2017
Q3 		$215K Sell
6,850
-450
-6% -$13.3K 0.03% 482
2017
Q2 		$205K Buy
+7,300
New +$165K 0.03% 465
2016
Q4 		– Sell
-10,950
Closed -$175K – 600
2016
Q3 		$175K Buy
10,950
+100
+0.9% +$1.51K 0.03% 485
2016
Q2 		$137K Sell
10,850
-100
-0.9% -$1.56K 0.02% 477
2016
Q1 		$216K Hold
10,950
– – 0.04% 430
2015
Q4 		$247K Sell
10,950
-250
-2% -$4.94K 0.05% 403
2015
Q3 		$264K Buy
11,200
+350
+3% +$9.66K 0.05% 396
2015
Q2 		$310K Sell
10,850
-300
-3% -$7.86K 0.05% 376
2015
Q1 		$288K Buy
11,150
+50
+0.5% +$1.14K 0.05% 391
2014
Q4 		$206K Buy
+11,100
New +$200K 0.03% 451

Other funds holding XENT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Moors & Cabot's XENT Position: Q1 2018 in Review

Moors & Cabot sold out of Intersect ENT, Inc (XENT) in Q1 2018, closing a stake of 6,600 shares — an estimated $211K sold.

Moors & Cabot first reported a position in XENT in Q4 2014 and held it in 11 quarters. The position peaked at $310K in Q2 2015. 172 funds tracked by Wall St. Rank hold XENT as of Q1 2018.

  • Moors & Cabot reported no remaining Intersect ENT, Inc position as of Q1 2018 after selling out during the quarter.
  • Moors & Cabot sold 6,600 Intersect ENT, Inc shares in Q1 2018, an estimated $211K.
  • Moors & Cabot first reported a position in Intersect ENT, Inc in Q4 2014 and held it in 11 quarters.
  • Moors & Cabot's Intersect ENT, Inc position peaked at $310K in Q2 2015.
  • 172 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q1 2018.

Based on Moors & Cabot's 13F filing for Q1 2018, filed 18 May 2018.